Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7VB
|
|||
| Former ID |
DNCL001693
|
|||
| Drug Name |
MBX-102
|
|||
| Synonyms |
Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 2/3 | [1] | |
| Company |
Metabolex
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H17ClF3NO4
|
|||
| Canonical SMILES |
CC(=O)NCCOC(=O)C(C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
|
|||
| InChI |
1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1
|
|||
| InChIKey |
BJBCSGQLZQGGIQ-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 24136-23-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00353587) Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin. U.S. National Institutes of Health. | |||
| REF 2 | MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.